
GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer
Author(s) -
Samantha M. Bevill,
José F. Olivares-Quintero,
Noah Sciaky,
Brian T. Golitz,
Darshan Singh,
Adriana S. Beltrán,
Naim U. Rashid,
Timothy J. Stuhlmiller,
Andrew Hale,
Nathaniel J. Moorman,
Charlene Santos,
Steven P. Angus,
Jon S. Zawistowski,
Gary L. Johnson
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/kjen-ha42
Subject(s) - bromodomain , triple negative breast cancer , apoptosis , cancer research , breast cancer , cancer , bet inhibitor , chemistry , medicine , biology , epigenetics , biochemistry , gene